fda compounding semaglutide warning november 2025 Untitled Compounded Semaglutide & Tirzepatide 2025:

New research suggests GLP-1 drugs may lower the risk of certain cancers, but could also raise the likelihood of developing kidney cancer.

Cheaper copies mean many more people will likely start taking these drugs, and not always under close specialist supervision, even though the rules say only certain doctors are allowed to prescribe them

Image Credit: Visual Capitalist Data: S&P global, GLP-1 Men, Financial times, IFEBP & Reuters #biotech #biopharma #GLP1 #obesity | 14 comments on LinkedIn

SUGGESTED USE: Adults take 1 capsule daily, or as recommended by your healthcare practitioner, with 8 ounces of water or your favorite beverage

Novo Nordisk scientist Lotte Bjerre Knudsen's discoveries helped kick off a revolution in how doctors think of and treat obesity.